Company DNIB Unwind Inc
Equities
BINDQ
US2332421062
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stephen Zale
CTO | Chief Tech/Sci/R&D Officer | 68 | 06-10-31 |
Tom Baker
IRC | Investor Relations Contact | - | - |
Neil Bander
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 16-07-23 | |
James L. Wright
PRN | Corporate Officer/Principal | 76 | 06-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Corporate Officer/Principal | - | 16-07-23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 20,886,802 | 17,860,424 ( 85.51 %) | 0 | 85.51 % |
Company contact information
DNIB Unwind, Inc.
333 South Grand Avenue Suite 4100
90071, Los Angeles
+617-491-3400
http://bindtherapeutics.com![address DNIB Unwind Inc(BINDQ)](https://cdn.zonebourse.com/static/address/31206046.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+18.90% | 125B | |
+13.75% | 108B | |
-7.50% | 24.21B | |
+2.07% | 22.78B | |
-10.79% | 17.96B | |
-41.74% | 16.43B | |
-14.18% | 16.37B | |
+1.71% | 13.58B | |
+27.80% | 11.66B |
- Stock Market
- Equities
- BINDQ Stock
- Company DNIB Unwind Inc